Fusion Protein comprising a glp-1r agonist, fgf-21 or Mimetic compound and a Pharmaceutical composition that comprises the Connector； Nucleic Acid； Coding； vector； host Cell； method of Preparation and use for treating cardiovascular disease, diabetes mellitus and / Or metabolic syndrome.
BOSCHEINEN, OLIVER,DREYER, MATTHIAS,HABERMANN, PAUL,SCHAEFER, HANS-LUDWIG,SOMMERFELD, MARK,LANGER, THOMAS
申请号：
CL2015000379
公开号：
CL2015000379A1
申请日:
2015.02.17
申请国别(地区):
CL
年份:
2015
代理人:
摘要：
The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to pharmaceutical compositions, medical uses and methods of treatment involving the fusion protein, particularly in the field of diabetes, dyslipidemia, obesity and/or adipositas.PROTEÍNA DE FUSIÓN QUE COMPRENDE UN AGONISTA DE GLP-1R, FGF-21 O UN COMPUESTO MIMÉTICO Y UN CONECTOR； COMPOSICIÓN FARMACÉUTICA QUE LA COMPRENDE； ÁCIDO NUCLEICO QUE LA CODIFICA； VECTOR； CÉLULA HUÉSPED； MÉTODO DE PREPARACIÓN； Y USO PARA TRATAR ENFERMEDAD CARDIOVASCULAR, DIABETES MELLITUS Y/O SÍNDROME METABÓLICO.
